Pharmaceutical sponsor
Hanmi Pharmaceutical Company Limited Clinical Trials
Studies where Hanmi Pharmaceutical Company Limited is the lead sponsor: its pipeline by phase, what is enrolling now and where. Studies it supports as a collaborator are in the search.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 11Erectile Dysfunction
A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
A Multicenter, Randomized, Double-blind, Phase Ⅲ Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
- Trial name
- NCT07899073
- Testing
- HIP2602 + HPP2602-2, HPP2602-1 + HPP2602-2, HGP1201 + HPP2602-1
- Where
- South Korea
- Volunteers
- 225 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes Mellitus, T2DM
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
This study is a Phase 2 clinical trial to evaluate the efficacy, safety, and tolerability of HM15275 in subjects with type 2 diabetes mellitus over 36 weeks.
- Trial name
- NCT07527650
- Testing
- HM15275
- Where
- 20 sites in United States
- Volunteers
- 180 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Advanced or Metastatic Solid Tumors
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and efficacy in patients with advanced…
- Trial name
- NCT06234397
- Testing
- BH3120, pembrolizumab
- Where
- 10 sites in United States, South Korea
- Volunteers
- 216 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
A multicenter, prospective, non-interventional, observational study to evaluate effectiveness and safety of sequential triple combination therapy (amlodipine/losartan/chlorthalidone) in Korean patients with hypertension
- Trial name
- AMPR-OS-2503 (NCT07784296)
- Testing
- AMOPREL TAB 1.67/16.67/4.17mg
- Where
- South Korea
- Volunteers
- 3,500 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Short Bowel Syndrome
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
This is a randomized, double-blind, placebo-controlled, proof-of-concept (PoC), Phase 2 study to assess the safety, PK, and PD of SC administration of HM15912(sonefpeglutide) in adult subjects with SBS-associated intestinal…
- Trial name
- NCT04775706
- Testing
- HM15912 Active
- Where
- 15 sites in United States, Belgium and 6 more
- Volunteers
- 18 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
- Trial name
- NCT07660796
- Testing
- HCP1803-3, HCP1803-4, RLD2001-1
- Where
- South Korea
- Volunteers
- 256 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Type 2 Diabetes
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin
- Trial name
- NCT07379333
- Testing
- HM11260C
- Where
- South Korea
- Volunteers
- 118 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity, Obese
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.
- Trial name
- NCT07219589
- Testing
- HM17321
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Advanced or Metastatic Melanoma
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
This is a Phase 2 open-label, multicenter, single-arm study evaluating the combination of Belvarafenib and Cobimetinib in patients with locally advanced or metastatic melanoma with NRAS mutations.
- Trial name
- NCT07449754
- Testing
- Belvarafenib, Cobimetinib
- Where
- 10 sites in South Korea
- Volunteers
- 45 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Healthy
A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers
The purpose of this study is to evaluate the pharmacokinetic characteristics and safety between HIP2503 and HCP1306 in healthy volunteers.
- Trial name
- NCT07297693
- Testing
- HIP2503, HCP1306
- Where
- South Korea
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Completed, with results posted
All 9Gastric Cancer
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
This clinical study is a Phase 2, open-label study to assess the efficacy, safety profile of FLX475 combined with pembrolizumab in patients with advanced or metastatic gastric cancer.
- Trial name
- NCT04768686
- Testing
- FLX475, Pembrolizumab
- Where
- 10 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Renal Impairment
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
An Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HM15912 in Subjects with Renal Impairment and Matched Control Subjects with Normal Renal Function
- Trial name
- NCT05711381
- Testing
- HM15912
- Where
- 4 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Pharmacology
Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects
A First-in-Human, Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912 in Healthy Korean Subjects
- Trial name
- NCT04076293
- Testing
- HM15912
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obesity
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Single ascending dose of HM15211 in healthy obese subjects.
- Trial name
- NCT03374241
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Obese With Comorbidities, Overweight With Comorbidities
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
- Conditions
- Obese With Comorbidities, Overweight With Comorbidities, Type2 Diabetes
- Trial name
- NCT04167553
- Testing
- HM15136
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited